Related Experiment Video
Updated: Oct 4, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.7K
Stopping Empagliflozin Unmasks Heart Failure
Morolake Amole1, Julio Leey-Casella1,2
1University of Florida College of Medicine, Gainesville.
Abstract:
SGLT2 inhibitors have been shown to have a role in the management of heart failure in patients with type 2 diabetes mellitus, but there is a risk of exacerbation when discontinued.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibitors aid heart failure management in type 2 diabetes. However, discontinuing these vital medications may worsen heart failure symptoms.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established treatments for type 2 diabetes mellitus.
- These agents demonstrate significant benefits in managing heart failure (HF).
Purpose of the Study:
- To investigate the clinical implications of discontinuing SGLT2 inhibitors in patients with heart failure and type 2 diabetes.
- To assess the risk of heart failure exacerbation upon cessation of SGLT2 inhibitor therapy.
Main Methods:
- Observational study design.
- Analysis of patient data including medication history and heart failure events.
- Comparison of outcomes between patients who discontinued and continued SGLT2 inhibitors.
Main Results:
- Discontinuation of SGLT2 inhibitors was associated with an increased risk of heart failure exacerbation.
- Patients experiencing discontinuation showed a higher incidence of hospitalization for heart failure.
Conclusions:
- The findings highlight a potential risk of worsening heart failure when SGLT2 inhibitors are stopped.
- Continued use of SGLT2 inhibitors is crucial for maintaining cardiovascular benefits in patients with type 2 diabetes and heart failure.
More Related Videos
Related Concept Videos
01:30Heart Failure V: Medical Management
39
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
39
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
550
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
550
01:22Heart Failure Drugs: Diuretics
519
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
519
01:26Heart Failure III: Clinical Manifestations
72
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
72
01:27Heart Failure I: Introduction
107
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
107
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K